Édith Borcoman
YOU?
Author Swipe
View article: MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer Open
Metronomic vinorelbine in combination with dual durvalumab plus tremelimumab immunotherapy had only moderate activity in pretreated advanced HNSCC.
View article: Common origin for effector and regulatory follicular and tissue-Adapted CD4+ T cells in Non-Small Cell Lung Cancer
Common origin for effector and regulatory follicular and tissue-Adapted CD4+ T cells in Non-Small Cell Lung Cancer Open
Tumor-invaded lymph nodes (LNs) serve as critical hubs for anti-tumor immunity, yet their role in orchestrating immune responses remains poorly understood. Using integrated single-cell RNA sequencing, T cell receptor sequencing, and chroma…
View article: Scandare: A Successful, Flexible, Prospective, and Longitudinal Biobank Framework
Scandare: A Successful, Flexible, Prospective, and Longitudinal Biobank Framework Open
Patient-specific tumor heterogeneity is a significant challenge to understanding and treating cancer. The availability of multi-omic data in large public repositories has powered breakthroughs in precision medicine by enabling diversified …
View article: Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study Open
This trial is registered with ClinicalTrials.gov, identifier NCT03518606.
View article: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial Open
View article: CD8 <sup>+</sup> T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance
CD8 <sup>+</sup> T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance Open
CD8+ T cells shape the antitumor immune response. Here, we evaluated CD8+ T cells expressing different levels of PD-1, their functional status, and distribution in different tissues of luminal breast cancer (BC) patie…
View article: Hpv Circulating Tumor DNA to Monitor Response to Pembrolizumab and Vorinostat Combination in Patients with Advanced Hpv-Related Squamous Cell Carcinomas
Hpv Circulating Tumor DNA to Monitor Response to Pembrolizumab and Vorinostat Combination in Patients with Advanced Hpv-Related Squamous Cell Carcinomas Open
View article: Development of a Prognostic Score in Patients With Advanced Breast Cancer Treated for Meningeal Carcinomatosis
Development of a Prognostic Score in Patients With Advanced Breast Cancer Treated for Meningeal Carcinomatosis Open
Purpose: Meningeal carcinomatosis (MC) has a dismal prognosis in patients with breast cancer and requires invasive therapies. The aim of the present retrospective study was to determine a prognostic score for overall survival (OS) in patie…
View article: Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study Open
Background The MOVIE phase I/II trial ( NCT03518606 ) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recu…
View article: The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification Open
Background: The European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) classification system provides a standardized framework for categorizing genomic alterations (GAs) of patients with recurren…
View article: 674 Preferential tumor retention of EGL-001, a CTLA-4/CD25 antagonist fusion protein, to selectively deplete tumor Tregs and minimize peripheral toxicities: towards a first-in-human clinical study
674 Preferential tumor retention of EGL-001, a CTLA-4/CD25 antagonist fusion protein, to selectively deplete tumor Tregs and minimize peripheral toxicities: towards a first-in-human clinical study Open
View article: Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer Open
View article: The genomic and transcriptomic landscape of metastastic urothelial cancer
The genomic and transcriptomic landscape of metastastic urothelial cancer Open
View article: Phase I trials of single-agent new drugs in head and neck cancer: a scoping review
Phase I trials of single-agent new drugs in head and neck cancer: a scoping review Open
Phase I trials of single agents designed for head and neck patients were generally safe but with a low ORR. Future development of new drugs dedicated for HNC patients that can more accurately reflect the heterogeneity of HNC and provide mo…
View article: Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study
Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study Open
View article: CD74 supports accumulation and function of regulatory T cells in tumors
CD74 supports accumulation and function of regulatory T cells in tumors Open
View article: Development of a prognostic score for meningeal carcinomatosis in patients with advanced breast cancer
Development of a prognostic score for meningeal carcinomatosis in patients with advanced breast cancer Open
Purpose Meningeal carcinomatosis carries a dismal prognosis in patients with breast cancer, and requires invasive therapies. The aim of the present retrospective study was to elaborate a prognostic score of overall survival in patients wit…
View article: Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine Open
View article: Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity Open
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase in…
View article: BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors Open
View article: 115P BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
115P BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study Open
View article: Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy
Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy Open
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase in…
View article: CD39 <sup>+</sup> conventional CD4 <sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade
CD39 <sup>+</sup> conventional CD4 <sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade Open
Conventional CD4+ T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characteriz…
View article: Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer
Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer Open
Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor…
View article: First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—<scp>ENCORE</scp>
First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—<span>ENCORE</span> Open
Background ENCORE, an observational, prospective, open‐label study, investigated real‐world treatment practices and outcomes with cetuximab plus platinum‐based therapy (PBT) in first‐line (1L) recurrent and/or metastatic squamous cell carc…
View article: CD74 supports Treg accumulation and function in tumors
CD74 supports Treg accumulation and function in tumors Open
Regulatory T cells (Tregs) are plastic cells playing a pivotal role in the maintenance of immune homeostasis. Tregs actively adapt to the microenvironment where they reside; as a consequence, their molecular and functional profiles differ …
View article: Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Purpose:Debio 1143 is an oral antagonist of inhibitor of apoptosis proteins, which enhances tumor response with concomitant chemoradiotherapy. Addition of Debio 1143 to cisplatin-based chemoradiotherapy in locally advanced squamous cell ca…
View article: Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Purpose:Debio 1143 is an oral antagonist of inhibitor of apoptosis proteins, which enhances tumor response with concomitant chemoradiotherapy. Addition of Debio 1143 to cisplatin-based chemoradiotherapy in locally advanced squamous cell ca…
View article: Supplementary Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Supplementary Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Supplementary Methods (DLT & efficay) and Tables S1 (Grade 3-4 AEs in {greater than or equal to}2 patients), S2 (late onset toxicity), S3 (PK parameters)
View article: Supplementary Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Supplementary Data from Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Open
Supplementary Methods (DLT & efficay) and Tables S1 (Grade 3-4 AEs in {greater than or equal to}2 patients), S2 (late onset toxicity), S3 (PK parameters)